Physician profile
Victoria E Grady
NPI 1043275852
$4,620.95
in general payments reported to CMS, 2019-2025
34 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $302 · 2021: $693 · 2022: $745 · 2023: $725 · 2024: $1,153 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482 · Education: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.31 |
| Education | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $824.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $735.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $499.07 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $481.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $330.11 | 2019-2025 | |
| Pfizer INC. | $329.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $266.12 | 2019-2025 | Shingrix, Arexvy, Rotarix |
| Otsuka America Pharmaceutical, INC. | $159.21 | 2023-2025 | Rexulti |
| Abbott Laboratories | $111.07 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $99.72 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $95.44 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $90.80 | 2021-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $58.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.01 | 2021-2024 | Jardiance, Tradjenta |
| Philips North America LLC | $49.86 | 2024 | (Ck6) Holter, (5050) Extended Holter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $45.15 | 2024-2025 | Fanapt |
| Exact Sciences Corporation | $44.67 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $37.45 | 2023-2025 | Nexletol |
| Sanofi Pasteur INC. | $34.87 | 2020-2023 | |
| Ironshore Pharmaceuticals INC. | $30.41 | 2019 | |
| Cranial Technologies, INC | $27.43 | 2020-2021 | |
| Biogen, INC. | $21.72 | 2019 | |
| Corium, LLC | $21.46 | 2023 | Azstarys |
| Lundbeck LLC | $21.42 | 2024 | Rexulti |
| Shire North American Group INC | $18.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.04 | 2022 | |
| Watermark Medical, INC. | $17.74 | 2024 | |
| Boston Scientific Corporation | $17.69 | 2019 | |
| Adlon Therapeutics L.P. | $15.45 | 2020 | |
| Neurelis, INC. | $15.16 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2019 | |
| Genentech USA, INC. | $11.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.